Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Reflect ScientificRSCF +6.26% Debt-to-EBITDA is 0.68 as of Sep. 2025. The stock has 4 warning signs investors should review. Among 470 Medical Devices & Instruments companies, Reflect Scientific ranks worse than 75.53% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Reflect Scientific's Debt-to-EBITDA or its related term are showing as below:
RSCF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.99 Med: -0.02 Max: 3.94
Current: 3.94
During the past 13 years, the highest Debt-to-EBITDA Ratio of Reflect Scientific was 3.94. The lowest was -0.99. And the median was -0.02.
RSCF's Debt-to-EBITDA is ranked worse than 75.53% of 470
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs RSCF: 3.94
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Reflect Scientific Debt-to-EBITDA Related Terms
Reflect Scientific Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Reflect Scientific's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RSCF vs NXGL, LUCY, GCTK: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Reflect Scientific's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Reflect Scientific Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Reflect Scientific's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Reflect Scientific's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Sep. 2025) EBITDA data.
Reflect Scientific (RSCF) has a Debt-to-EBITDA of 0.68 as of Sep. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Reflect Scientific. According to the industry distribution chart, Reflect Scientific ranks #355 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 75.5%.
Is Reflect Scientific's Debt-to-EBITDA too high?
Reflect Scientific's current Debt-to-EBITDA is 0.68. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.59. Reflect Scientific's value of 0.68 is 57.1% below this industry median. Based on the distribution chart, Reflect Scientific ranks #355 out of 470 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Reflect Scientific's Debt-to-EBITDA compare to NXGL and LUCY?
According to the Medical Devices & Instruments industry distribution chart, Reflect Scientific ranks #355 out of 470 companies for Debt-to-EBITDA. This places Reflect Scientific in the lower half of its industry. The industry median Debt-to-EBITDA is 1.59. Reflect Scientific's value of 0.68 is 57.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Reflect Scientific's current Debt-to-EBITDA of 0.68 is 57.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Reflect Scientific. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Reflect Scientific's current Debt-to-EBITDA is 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reflect Scientific stock overvalued right now?
Reflect Scientific (RSCF) has a current Debt-to-EBITDA of 0.68. The current Debt-to-EBITDA is 0.68 and 57.1% below the Medical Devices & Instruments industry median of 1.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Reflect Scientific (RSCF), the current Debt-to-EBITDA is 0.68 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Reflect Scientific Inc is engaged in the manufacture and distribution of products targeted at the life science market. The group's customers include hospitals, diagnostic laboratories, pharmaceutical and biotech companies, cold chain management, universities, government and private sector research facilities, and chemical and industrial companies. Its growing product portfolio includes ultra-low temperature freezers, blast freezers, solvent chillers, and refrigerated transportation in addition to supplying OEM products to the life sciences industry. The group's products are Cryometrix, GCFerrules, and Visacon. It recognizes revenue from the sale of scientific equipment for the life sciences and manufacturing industries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RSCF has been successfully added to your 
